XOMA Royalty LLC ends $200M shelf registration
Rhea-AI Filing Summary
XOMA Royalty LLC filed a post-effective amendment to its Form S-3 shelf registration originally covering $200 million of various securities, including unsecured debt, common and preferred stock, depositary shares, subscription rights, contingent value rights, royalty certificates, warrants and units. Following a restructuring in which XOMA Royalty Corporation converted from a Nevada corporation to a Delaware limited liability company and a subsequent merger where Flex Merger Sub, Inc. merged with XOMA Royalty Holdings Corporation to become a wholly owned subsidiary of Ligand Pharmaceuticals Incorporated, all offerings under the shelf have been terminated. This amendment removes from registration all securities that were registered but remained unsold under the S-3 as of the filing date.
Positive
- None.
Negative
- None.
Key Figures
Shelf registration size: $200 million
Merger Agreement date: April 27, 2026
Merger completion date: July 14, 2026
+1 more
4 metrics
Shelf registration size
$200 million
Amount of securities registered on Form S-3 (File No. 333-277794)
Merger Agreement date
April 27, 2026
Date of Agreement and Plan of Merger among XOMA entities and Ligand
Merger completion date
July 14, 2026
Date Merger Sub merged with XOMA Royalty Holdings Corporation
Post-effective amendment filing date
July 20, 2026
Date the Registrant caused the post-effective amendment to be signed
Key Terms
post-effective amendment, Registration Statement on Form S-3, Agreement and Plan of Merger, Conversion, +1 more
5 terms
post-effective amendment regulatory
"This post-effective amendment No. 1 relates to the Registration Statement"
A post-effective amendment is an official update to a securities registration document filed after that document has become effective with regulators; it corrects, adds or replaces information about the securities, the company, or an offering. Investors care because it keeps the legal record current and can change what is being sold or the rights attached to shares — like getting a revised product manual after a launch that may affect value or use.
Registration Statement on Form S-3 regulatory
"relates to the Registration Statement on Form S-3 (File No. 333-277794)"
A registration statement on Form S‑3 is a short, standardized filing a qualified public company uses to register new securities with regulators so they can be sold to investors; think of it as a pre-approved, reusable permission slip that speeds up future offerings. It matters to investors because it lets the company raise money more quickly and cheaply — which can fund growth or pay debt — but may also lead to share dilution or change in ownership, so it affects value and liquidity.
Agreement and Plan of Merger regulatory
"pursuant to the terms of the Agreement and Plan of Merger (the “Merger Agreement”)"
An Agreement and Plan of Merger is a formal document where two companies agree to combine into one, outlining how the process will happen. It’s like a step-by-step plan for merging, and it matters because it shows both sides have agreed on the details before the official transition takes place.
Conversion regulatory
"the Registrant converted from a Nevada corporation to a Delaware limited liability company (the “Conversion”)"
Conversion is the exchange of one type of financial instrument for another, most commonly turning convertible bonds or preferred shares into common stock. It matters to investors because conversion changes the number of outstanding shares and ownership stakes—like trading a coupon for a slice of a company—potentially reducing each existing owner's portion, affecting per-share earnings, voting power and the market value of the stock.
royalty certificates financial
"royalty certificates representing the contractual right to receive royalties from the Registrant"
Royalty certificates are tradable claims that give the holder a right to a portion of future payments tied to an asset’s revenue—such as a patent, drug sales, mineral production, or a licensing deal. For investors they act like buying a steady slice of a future cashflow stream: returns depend on how well the underlying asset performs, offering potential income and diversification but also exposure to the asset’s commercial risk.
Offering Details
shelf
Offering
Offering Type
shelf
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does XOMA (XOMA) do in this post-effective amendment?
XOMA Royalty LLC files a post-effective amendment to its Form S-3 to remove from registration all unsold securities that had been registered under a prior $200 million shelf registration.
How large was the original XOMA (XOMA) shelf registration?
The original Form S-3 shelf registration covered $200 million of securities, including unsecured debt, common and preferred stock, depositary shares, subscription rights, contingent value rights, royalty certificates, warrants and units.
Why is XOMA (XOMA) deregistering these securities?
XOMA is deregistering the securities because, following a merger with entities affiliated with Ligand Pharmaceuticals Incorporated, it has terminated all offerings under the Form S-3 shelf registration.
What corporate changes occurred at XOMA (XOMA) before deregistration?
Before deregistration, XOMA Royalty Corporation completed a Conversion from a Nevada corporation to a Delaware limited liability company and then participated in a merger under an Agreement and Plan of Merger dated April 27, 2026.
Which securities types are affected by XOMA (XOMA)'s deregistration?
The deregistration affects all unsold securities previously registered, including unsecured debt securities, common stock, preferred stock, depositary shares, subscription rights, contingent value rights, royalty certificates, warrants and units.
Who is the new parent company in the XOMA (XOMA) merger structure?
After the merger, XOMA Royalty Holdings Corporation became a wholly owned subsidiary of Ligand Pharmaceuticals Incorporated, which is identified as the Parent in the Agreement and Plan of Merger.
AI-generated analysis. How Rhea-AI works. Not financial advice.
